Clinical trials: Aml
Acute Myeloid Leukemia, AML, Childhood
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or…
- Conditions
- Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML, Refractory Pediatric AML
- Trial name
- Pediatric AML (NCT05622591)
- Testing
- ELU001
- Sponsor
- Elucida Oncology
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc
Leukemia, Myeloid, Acute
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed…
- Trial name
- NCT02670044
- Testing
- Cobimetinib, Idasanutlin, Venetoclax
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401…
- Trial name
- NCT02270463
- Testing
- Tagraxofusp-erzs
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
Leukemia, Myelocytic, Acute, Infusions, Intravenous
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
The purpose of this study is to evaluate the effect of corticosteroids on the frequency and severity of Mylotarg® infusion-related adverse events, to evaluate the effect of corticosteroids on the efficacy of Mylotarg® induced…
- Trial name
- NCT00304447
- Testing
- Mylotarg
- Volunteers
- 30 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.
- Trial name
- NCT06282549
- Testing
- Telmisartan/Amlodipine/Chlorthalidone(Truset)
- Where
- 5 sites in South Korea
- Volunteers
- 1,219 people
- Sponsor
- Yuhan Corporation
Leukemia, Acute Myeloid Leukemia
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
This is a single-arm, single-dose dose-escalation and dose-expansion study.
- Trial name
- NCT06347458
- Testing
- BG1805
- Volunteers
- 24 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Advanced Solid Tumors, Acute Myeloid Leukemia
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical…
- Trial name
- NCT02561455
- Testing
- Gilteritinib
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Leukemia, Myeloid, Acute
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Phase I Dose Escalation: Primary objective is to determine the Maximum Tolerated Dose (MTD) and the recommended dose for Phase I Extension.
- Trial name
- NCT02632721
- Testing
- Decitabine, BI 836858
- Where
- 14 sites in United States, Germany and 2 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy…
- Trial name
- NCT02873338
- Testing
- Dociparstat sodium, Idarubicin, Cytarabine
- Where
- 23 sites in United States
- Volunteers
- 75 people
- Sponsor
- Jazz Pharmaceuticals